Unveiling the influence of Naftidrofuryl against lipopolysaccharide-induced lung injury model: Insights into inflammatory pathways
The American Journal of the Medical Sciences · 2026-07 · 372 (1) · 72-80
DOI: 10.1016/j.amjms.2026.04.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of the Medical Sciences, 2026-07. Verfasst von Abdulrahman S Bahashwan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, College of Medicine, Taibah University, Kingdom of Saudi Arabia. Hauptthemen laut MEDLINE: Lipopolysaccharides, Acute Lung Injury, Inflammation. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Acute lung injury (ALI) is a serious inflammatory condition caused by several insults, including LPS-induced immunity dysregulation, among others. In vitro and in vivo models are used to study the protective effect of Naftidrofuryl (NAF) against LPS-induced lung injury. METHODS Murine RAW 264.7 cells were treated with NAF (10 µM). In addition, NAF (45 mg/kg) was injected intraperitoneally in a rat model for 28 days to assess its effects on LPS-induced acute lung injury (3 mg/kg). Several biomarkers in vitro cells and rat model tissue were used to investigate the mechanisms. ELISA, western blotting, and immunohistochemistry were used. RESULTS LPS caused RAW 264.7 cells to express higher levels of CD11b, CD38, and CD206, indicating macrophage activation and inflammation. In rats, LPS increased CXCL1 and CXCL2 levels, NFκB activity, pyroptosis, and IL-1β via GSDMD signaling. Histopathological analysis and scoring showed that NAF treatment reduced LPS-induced ALI by normalizing biomarker levels and lung tissue damage. CONCLUSIONS The findings showed that NAF can regulate innate immune responses, suppress inflammation, and reduce lung injury in LPS-induced ALI. These findings aid the development of anti-inflammatory treatments for bacterial and inflammatory pulmonary diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Medical Sciences, College of Medicine, Taibah University, Kingdom of Saudi Arabia.
- Department of Clinical Pharmacy, Al-Azhar University, Assiut branch, Assiut 71524, Egypt.
- Department of Pathology, Faculty of Veterinary Medicine, Matrouh University, Marsa Matruh, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Egypt. Electronic address: Dr.moda88@gmail.com.
Zitieren
APA
Bahashwan, A. S., El-Shoura, E. A. M., Saad, H. M., & Zaafar, D. (2026). Unveiling the influence of Naftidrofuryl against lipopolysaccharide-induced lung injury model: Insights into inflammatory pathways. The American Journal of the Medical Sciences, 372(1), 72-80. https://doi.org/10.1016/j.amjms.2026.04.003
Vancouver
Bahashwan AS, El-Shoura EAM, Saad HM, Zaafar D. Unveiling the influence of Naftidrofuryl against lipopolysaccharide-induced lung injury model: Insights into inflammatory pathways. The American Journal of the Medical Sciences. 2026;372(1):72-80. doi:10.1016/j.amjms.2026.04.003
BibTeX
@article{Bahashwan2026,
author = {Bahashwan, Abdulrahman S and El-Shoura, Ehab A M and Saad, Hebatallah M and Zaafar, Dalia},
title = {Unveiling the influence of Naftidrofuryl against lipopolysaccharide-induced lung injury model: Insights into inflammatory pathways},
journal = {The American Journal of the Medical Sciences},
year = {2026},
volume = {372},
number = {1},
pages = {72--80},
doi = {10.1016/j.amjms.2026.04.003}
}
EUVIMED